Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Net Income (2016 - 2026)

Akebia Therapeutics has reported Net Income over the past 10 years, most recently at -$12.2 million for Q4 2025.

  • Quarterly Net Income rose 46.31% to -$12.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$5.3 million through Dec 2025, up 92.3% year-over-year, with the annual reading at -$5.3 million for FY2025, 92.3% up from the prior year.
  • Net Income was -$12.2 million for Q4 2025 at Akebia Therapeutics, down from $540000.0 in the prior quarter.
  • Over five years, Net Income peaked at $29.0 million in Q2 2022 and troughed at -$84.3 million in Q2 2021.
  • The 5-year median for Net Income is -$16.2 million (2023), against an average of -$25.4 million.
  • Year-over-year, Net Income surged 134.44% in 2022 and then tumbled 3814.01% in 2024.
  • A 5-year view of Net Income shows it stood at -$70.4 million in 2021, then soared by 90.76% to -$6.5 million in 2022, then skyrocketed by 109.44% to $614000.0 in 2023, then tumbled by 3814.01% to -$22.8 million in 2024, then soared by 46.31% to -$12.2 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Net Income are -$12.2 million (Q4 2025), $540000.0 (Q3 2025), and $247000.0 (Q2 2025).